Literature DB >> 27466990

The effect of sequential transcatheter arterial chemoembolization (TACE) and portal venous embolizations (PVE) vs. TACE or PVE alone on rabbit VX2 liver carcinoma and on liver regeneration.

W-C Guo1, X-F He, Y-H Li, Z-H Li, Q-L Mei, Y Chen.   

Abstract

OBJECTIVE: This study aimed to build VX2 liver tumor model in rabbits and to investigate the sequential transcatheter arterial chemoembolization (TACE) and portal vein embolizations (PVE) vs. TACE or PVE alone on rabbit VX2 liver carcinoma and liver regeneration.
MATERIALS AND METHODS: VX2 liver tumor models were built in the rabbit. Rabbits carrying VX2 liver tumors were divided into four groups, including TACE+PVE, TACE, PVE and Sham groups respectively. Hematoxylin and eosin (HE) staining was performed to visualize the structures of tumor tissues. The volume data of caudal liver on day 3 and day 7 was measured by CT. Western blot analysis of active caspase-3 was performed to examine cell apoptosis. Immunohistochemical (IHC) staining of Ki-67 was performed to visualize hepatocyte regeneration. Serum IL-6, TNF-alpha, HGF and TGF-beta1 on 6th h, 24th h, day 3 and day 7 were measured by ELISA assay.
RESULTS: The TACE+PVE group had the strongest suppressive effect on tumor growth and induced the highest level of tumor cell apoptosis. TACE+PVE can induce evident liver regeneration, which is reflected by the largest caudal liver volume increase and the highest ratio of Ki-67 positive cells. ELISA assay showed that during the first 7 days since day 0, TACE+PVE group had the highest level of HGF, IL-6 and TNF-alpha.
CONCLUSIONS: TACE+PVE can significantly inhibit VX2 tumor growth, induce tumor cell apoptosis and liver regeneration, the effects of which are stronger than TACE or PVE alone. In the first 7 days since day 0, TACE+PVE group had the highest level of IL-6, TNF-alpha and HGF. This might be the reason why TACE+PVE induced the strongest liver regeneration.

Entities:  

Mesh:

Year:  2016        PMID: 27466990

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Liver Injury and Tumor-Inhibiting Effect of Sequential Transcatheter Arterial Chemoembolization and Portal Venous Embolization on Rabbit VX2 Liver Carcinoma.

Authors:  Dongda Song; Minggen Hu; Weichang Guo
Journal:  Med Sci Monit       Date:  2017-03-27

2.  Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new?

Authors:  Ze-Feng Zhang; Yu-Jun Luo; Quan Lu; Shi-Xue Dai; Wei-Hong Sha
Journal:  World J Clin Cases       Date:  2018-09-06       Impact factor: 1.337

3.  Expression of MMP-2 in residual VX2 liver tumor after transcatheter arterial embolization combined with portal venous embolization in an animal model.

Authors:  Ning Wei; Ziqiang Wu; Dong Lu; Jingkun Xiao; Chunze Zhou; Senlin Chu; Weifu Lv
Journal:  J Interv Med       Date:  2020-08-16

Review 4.  Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review.

Authors:  Zhiying Shao; Xin Liu; Chanjuan Peng; Liping Wang; Dong Xu
Journal:  World J Surg Oncol       Date:  2021-10-01       Impact factor: 2.754

Review 5.  Oncological benefits of portal vein embolization for patients with hepatocellular carcinoma.

Authors:  Toru Beppu; Kensuke Yamamura; Hirohisa Okabe; Katsunori Imai; Hiromitsu Hayashi
Journal:  Ann Gastroenterol Surg       Date:  2020-12-13

6.  Effect of curcumin-lipiodol emulsion combined with absorbable anti-adhesion film through double embolic pathway on angiogenesis and overall survival (OS) time of VX2 liver cancer rabbits.

Authors:  Chuanyu Yang; Zheng Xu; Kai Nie; Jing Liu
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.